Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692926 · ClinicalTrials.gov registry record · Phase 1
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
A Phase 1 study of MDS and Inborn Errors of Metabolism, sponsored by Joanne Kurtzberg, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT00692926: Completed Phase 1 study of MDS and Inborn Errors of Metabolism, sponsored by Joanne Kurtzberg, MD.
NCT00692926 is a Phase 1 study of MDS and Inborn Errors of Metabolism that has completed, run by Joanne Kurtzberg, MD. The registered enrollment target is 37 participants, below the 95-participant average among 22 other MDS trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00692926, a Phase 1 study of MDS and Inborn Errors of Metabolism, has completed, sponsored by Joanne Kurtzberg, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this investigational (not approved by the FDA) Phase I research is to test whether transplantation of umbilical cord blood cells can be safely supplemented with a transfusion of a portion of these cells that have been sorted (collected from a special machine called a cell sorter) and then either infused a few hours after the standard transplant or for some patients grown in a special system in the laboratory prior to the transplant, designed to increase the number of stem cells transplanted. This system is currently in the early phases of testing.
Conditions Studied
Interventions
- BIOLOGICAL ALDHbr Umbilical Cord Blood Cells
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-10 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
What the finished NCT00692926 record still lists
NCT00692926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 95-participant average among 22 other MDS trials with a reported enrollment target (61% lower).
The record links to 5 conditions, with MDS appearing as the primary indexed condition, and to 1 intervention - of which ALDHbr Umbilical Cord Blood Cells is the first listed.
NCT00692926 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00692926 about?
NCT00692926 is a clinical study titled "Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells". The main purpose of this investigational (not approved by the FDA) Phase I research is to test whether transplantation of umbilical cord blood cells can be safely supplemented with a transfusion of a portion of these cells that have been sorted (collected from a special machine called a cell sorter)...
What is the current status of trial NCT00692926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2005-10. Estimated completion is 2012-07.
What conditions does trial NCT00692926 study?
This clinical trial studies the following conditions: MDS, Inborn Errors of Metabolism, Anemia, Aplastic, Congenital Marrow Failure, Congenital Immunodeficiency Syndrome.
What interventions are being tested in trial NCT00692926?
The interventions under investigation include: ALDHbr Umbilical Cord Blood Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00692926?
This trial is sponsored by Joanne Kurtzberg, MD, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00692926 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00692926's enrollment target sits among peer trials
37 13th of 22 higher than 9 of 22 other MDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other MDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia